Presence of lysine at aa 335 of the hemagglutinin-neuraminidase protein of mumps virus vaccine strain Urabe AM9 is not a requirement for neurovirulence

The recent global resurgence of mumps has drawn attention to the continued need for robust mumps immunization programs. Unfortunately, some vaccines derived from inadequately attenuated vaccine strains of mumps virus have caused meningitis in vaccinees, leading to withdrawal of certain vaccine strains from the market, public resistance to vaccination, or in some cases, cessation of national mumps vaccination programs. The most widely implicated mumps vaccine in cases of postvaccination meningitis is derived from the Urabe AM9 strain, which remains in use in some countries. The Urabe AM9 vaccine virus has been shown to exhibit a considerable degree of nucleotide and amino acid heterogeneity. Some studies have specifically implicated variants containing a lysine residue at amino acid position 335 in the hemagglutinin-neuraminidase (HN) protein with neurotoxicity, whereas a glutamic acid residue at this position was associated with attenuation. To test this hypothesis we generated two modified Urabe AM9 cDNA clones coding either for a lysine or a glutamic acid at position 335 in the HN gene. The two viruses were rescued by reverse genetics and characterized in vitro and in vivo. Both viruses exhibited similar growth kinetics in neuronal and non-neuronal cell lines and were of similar neurotoxicity when tested in rats, suggesting that amino acid 335 is not a crucial determinant of Urabe AM9 growth or neurovirulence.     

Stromal progenitor cell therapy corrects the wound-healing defect in the ischemic rabbit ear model of chronic wound repair

Chronic wounds create a formidable clinical problem resulting in considerable morbidity and healthcare expenditure. The etiology for wound healing impairment appears to be multifactorial; however, ischemia is a common factor in most types of chronic wounds. Ideal therapy for such wounds would be to correct deficiencies in growth factors and matrix components and provide cellular precursors required for timely wound closure. We hypothesized that stromal progenitor cell (SPC) therapy could correct the ischemic wound-healing defect through both direct and indirect mechanisms. To test this hypothesis, we used the ischemic rabbit ear model of chronic wound healing. We found that treatment of the wounds with SPCs was able to reverse the ischemic wound-healing impairment, with improved granulation tissue formation and reepithelialization compared with vehicle or bone marrow mononuclear cell controls. In vitro, SPCs were found to produce factors involved in angiogenesis and reepithelialization, and extracellular matrix components, providing evidence for both direct and indirect mechanisms for the observed correction of the healing impairment in these wounds. Treatment of ischemic wounds with SPCs can dramatically improve wound healing and provides a rationale for further studies focused on SPCs as a potential cellular therapy in impaired wound healing.     

桡骨远端关节内骨折外固定器治疗的相关机制和原则探讨

目的 分析和探讨桡骨远端关节内骨折外固定器治疗的相关机制和原则.方法 笔者采用Orthofix外固定器和国产组合式外固定器治疗桡骨远端关节内骨折45例46肢,以齐藤英彦法对资料完整的37例38肢病例进行分型,分析其影像学表现、损伤和治疗相关机制以及特点.结果 各型复位方向和外固定腕关节位置均与致伤暴力方向相反.骨折愈合时间平均为43 d(37～62 d),平均随访时间14个月(3～56个月),按Dienst标准评估腕关节功能及疗效:优21例22肢,良10例10肢,可6例6肢.结论 闭合复位外固定能很好地解决桡骨远端关节内骨折的治疗问题,特别适用于粉碎型关节内骨折.其治疗原则是复位方向及腕关节外固定位置与损伤机制、移位情形相反,个别骨折块辅以切开复位时须强调有限切开,必须重视部分病例伴有的同侧桡骨中远段骨折和同侧尺骨远段骨折的处理.     

A CT-free, intra-operative planning and navigation system for minimally invasive anterior spinal surgery - an accuracy study.

OBJECTIVE: A comprehensive study was performed to evaluate the accuracy of a newly developed CT-free, intra-operative planning and navigation system for anterior spine surgery. MATERIALS AND METHODS: Instruments and an image intensifier were tracked using the SurgiGATE navigation system. A laboratory study was performed on 27 plastic vertebrae. Fiducial markers were implanted in the vertebrae for accuracy evaluation purposes, and a dynamic reference base was placed on the vertebrae to establish a patient coordinate system (P-COS). Two fluoroscopic images were used for intra-operative planning. The graft bed plan was recorded in P-COS, followed by surgical formation of the graft bed, which was visualized. To evaluate the accuracy, the vertebrae were scanned with CT, and the markers were used to calculate an accurate paired-point registered transformation between the CT coordinate system and P-COS. RESULTS: Using the new SPO module, accurate planning and navigation of a resection of the vertebral body is possible using two fluoroscopic images. The overall mean error between the planned resection volume and the actual resection was 0.98 mm. In addition, the module can serve as an educational tool for training spine surgeons. CONCLUSIONS: The new fluoroscopy-based system can be used safely for accurate performance of anterior resection during spondylodesis. New methods for safe and accurate registration during anterior spine surgery need to be developed.     

丹芎瘢痕涂膜的临床应用研究

目的:本文通过769例病人应用丹芎瘢痕涂膜防治瘢痕增生的治疗效果,为烧烫伤后瘢痕增生提供一种新的治疗手段.方法:我们根据中医、中药活血化淤原理,经多年临床实践研制而成的丹芎瘢痕涂膜,由丹参、川芎等复方组成.药物使用,将丹芎瘢痕涂膜直接均匀涂于瘢痕表面上,形成药膜,次日揭去药膜,重新涂药,每日1次,连续用药5个月.疤痕止痒软化膏对照,每日1次,连续用药5个月.结果:(1)创面愈合后瘢痕刚开始增生者,丹芎瘢痕涂膜治疗组共415例,显效77例,有效323例,总有效率96.39%;疤痕止痒软化膏同体对照组51例,显效0例,有效20例,总有效率39.22%,治疗组显著优于对照组.(2)创面愈合后瘢痕已增生者,丹芎瘢痕涂膜治疗组354例,显效88例,有效257例,总有效率97.46%;疤痕止痒软化膏对照组63例,显效4例,有效34例,总有效率60.32%,治疗组显著优于对照组.(3)丹芎瘢痕涂膜治疗组与疤痕止痒软化膏对照组综合疗效比较,丹芎瘢痕涂膜治疗组769例,显效165例,有效580例,总有效率96.88%;疤痕止痒软化膏对照组114例,显效4例,有效54例,总有效率50.88%,治疗组显著优于对照组.(4)60例丹芎瘢痕涂膜治疗组与同体空白对照组比较,治疗组显效25例,有效34例,总有效率98.33%;对照组显效0例,有效11例,总有效率18.33%;治疗组显著优于对照组.(5)未发现不良反应.结论:经769例病人临床应用丹芎瘢痕涂膜,并与已知疤痕止痒软化膏比较,丹芎瘢痕涂膜治疗效果显著优于疤痕止痒软化膏,丹芎瘢痕涂膜是一种安全、有效、新的创面瘢痕外用药.     

甲醛对小鼠致突变作用的研究

目的　研究甲醛对小鼠的致突变作用。方法　选择健康昆明种小鼠 5 0只 (雌雄各半 ) ,随机分为 3个剂量组 :甲醛高剂量组 (2 0 0 0mg/kg·bw)、中剂量组 (2 0 0mg/kg·bw)、低剂量组 (0 2 0mg/kg·bw) ,1个阴性对照组 (生理盐水 )和 1个阳性对照组 (环磷酰胺 5 0mg/kg) ,采用腹腔注射染毒 ,每天 1次 ,连续 5d。于第六天处死雌性小鼠进行骨髓细胞微核试验 ,于第三十五天处死雄性小鼠进行精子畸形试验 ,显微镜下观察并计数微核及畸形精子数。结果　甲醛中、高剂量组骨髓细胞微核数显著高于阴性对照组 (P <0 0 5 ;) ,同时低、中、高剂量组精子畸形率显著高于阴性对照组 (P <0 0 1)。结论　甲醛对小鼠具有致突变作用     

荧光示踪法研究逆行岛状皮瓣静脉回流

目的探讨采用荧光示踪法研究逆行岛状皮瓣静脉回流的可行性，并初步观察静脉回流规律。方法20只新西兰大白兔，每只取耳静脉血0．ImL，分离RBC并用FITC标记。流式细胞仪检测已标记的RBC阳性率及荧光强度，倒置荧光显微镜观察其形态。取20只新西兰大白兔，在动物双侧后肢内侧分别建立4cm&#215;3cm隐动、静脉逆行岛状皮瓣模型（n=10）和顺行岛状皮瓣模型（n=10），血管蒂长3cm。将一侧后肢随机设定为实验组，皮瓣制备后注射已标记的RBC悬液5pL；对侧为对照组，不注射示踪剂。实验组按顺行和逆行皮瓣分成两组，即顺行皮瓣组和逆行皮瓣组，每组10个；再根据注入示踪剂途径不同，分为动脉和静脉2个亚组，每亚组5个皮瓣。注射示踪剂5S后取下皮瓣立即冷冻，取连续的3张冰冻切片（5～7pm），其中2张行HE染色和GENMED染色，另]张不染色直接压片，荧光显微镜观察荧光分布。结果流式细胞仪分析FITC标记的RBC阳性率在99％以上，荧光强度均≥10。；倒置荧光显微镜下标记的RBC呈均匀分布的绿色荧光，荧光强度均匀、稳定。冰冻切片显示实验组皮瓣蒂部均出现荧光，对照组未见荧光。顺行岛状皮瓣组荧光主要分布在静脉腔、静脉壁、动脉内膜和外膜；逆行岛状皮瓣组荧光分布在动脉内膜、外膜和静脉壁。结论荧光示踪剂可用于静脉回流研究，顺行岛状皮瓣静脉主要通过静脉腔、静脉壁、动脉内膜和外膜回流；逆行岛状皮瓣静脉主要通过动脉内膜、外膜和静脉壁的“迷宫式途径”回流。     

Comparison of survival by allocation to medical therapy, surgery, or heart transplantation for ischemic advanced heart failure.

BACKGROUND: To ascertain survival of ischemic advanced heart failure patients by treatment allocation, we examined the outcome of transplant assessment patients allocated to medical therapy, high-risk conventional surgery, or transplantation. METHODS: Patients were identified from the Papworth transplant database and excluded if primary etiology was not ischemic. Grouping was undertaken according to treatment allocation at initial assessment, and analysis was performed by intention to treat. Survival was computed from the time of assessment and Cox regression used to stratify patients according risk with the Heart Failure Survival Score. RESULTS: From May 1993 to September 2001, a total of 755 patients were admitted for transplant assessment, with 348 (46.1%) identified as having heart failure of ischemic origin. Variables required for calculation of the Heart Failure Survival Score was available in 273 patients (78.4%), and 20 patients (7.3%) were lost to follow-up. Of the remaining 253 patients, 89 (35.2%) were allocated to medical therapy, 32 (12.6%) to surgery, and 132 (52.2%) to transplantation. The relative risk (95% confidence limit) of death compared with medical therapy was 0.62 (0.28, 1.40) for surgery and 0.38 (0.24, 0.61) for transplantation in medium- to high-risk patients. For low-risk patients, the relative risks for death compared with medical therapy were 1.87 (0.63, 5.60) for surgery and 1.97 (0.79, 4.96) for transplantation. CONCLUSIONS: Transplantation improved survival of medium- and high-risk patients compared with medical therapy. In the low-risk group, this was not evident. However, repeated assessment of risk is required because the hazard for death rises steadily after the third year in these patients.     

克林霉素国内外制剂的研究进展

1克林霉素研究历史概况1963年Mason等首先提出用林可霉素母核合成克林霉素的设想,直到1966年由Magerlein等才合成克林霉素。克林霉素最早由美国普强公司首先开发成功,并于1969年取得美国专利权。1968年率先在瑞士上市,商品名:Dalacin。我国于1975年开发研制成功,此后国内很多厂都投入生产。目前克林霉素常与庆大霉素、氨曲南或其它抗菌药品联用治疗需氧-厌氧菌感染。近年来有报道用克林霉素治疗寻常座疮(外用)、艾滋病患者的肺囊虫和弓形虫感染以及消化道、皮肤、软组织、骨髓炎、妇产科的感染控制,并取得了良好疗效。克林霉素(clindamyci…     

富含血管的听神经瘤

目的探讨富含血管的听神经瘤的手术治疗。方法复习20年（1975—1995）手术治疗单侧听神经瘤90例，其中4例为富含血管的听神经瘤（HAT），与86例非富含血管的听神经瘤（NHAT），做回顾性分析，据临床表现、放射学检查、手术所见做比较。结果HAT较NHAT年轻（28±10与54±17岁）（P〈0．01），MRI显示HAT为实质性，无肿瘤囊变，多数较NHAT为大（P〈0．05）；MRI示HAT有多个代表较大引流静脉的流空效应；经皮股动脉、椎动脉造影显示HAT有广泛的肿瘤着色及早期引流静脉的充盈，并证实由椎基动脉供血。过去文献报道认为以分期手术为宜。作者在控制性低血压麻醉下，成功地完成了4例HAT的切除术，未输血，术后无明显伤残。结论HAT是一种实质性大型肿瘤，出现于青年期，血管造影能够提供特征性发现。MRI能显示肿瘤表面的流空效应而确诊。采用控制性低血压麻醉有望能一期全切除肿瘤。